High incidence and reversible bradycardia events following alectinib initiation

BACKGROUND: With the widespread use of alectinib in patients with anaplastic lymphoma kinase (ALK)‐positive non‐small‐cell lung cancer (NSCLC), its cardiotoxicity has gradually emerged, including new‐onset sinus bradycardia (SB). However, the incidence, timing, severity, and risk factors of alectini...

Descripción completa

Detalles Bibliográficos
Autores principales: Yuan, Dongqi, Zhu, Fuyi, Zuo, Ran, Wang, Yu, Huo, Gengwei, Cui, Jinfang, Yue, Ping, Chen, Peng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9925342/
https://www.ncbi.nlm.nih.gov/pubmed/36535917
http://dx.doi.org/10.1111/1759-7714.14769

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9925342/
https://www.ncbi.nlm.nih.gov/pubmed/36535917
http://dx.doi.org/10.1111/1759-7714.14769

Ejemplares similares